Sales of Skyrizi and Rinvoq, AbbVie's two new immunology drugs, jumped higher in the fourth quarter, leading the pharma to raise its 2020 forecasts for them by more than two-thirds.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,